Systemic sclerosis (SSc) is a chronic autoimmune disease characterised by skin and
internal organs fibrosis, vascular damage and positive antinuclear autoantibodies
(ANAs). The classical antigenic specificities of ANAs are anti-centromere (ACA), anti-topoisomerase
I antibodies (anti-topo I) and the more recently described anti-RNA polymerase III
antibodies (anti-RNAPIII).
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis.J Clin Invest. 1993; 91: 1399-1404https://doi.org/10.1172/JCI116343
- 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.Arthritis Rheum. 2013; 65: 2737-2747https://doi.org/10.1002/art.38098
- Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis.Arthritis Rheumatol Hoboken NJ. 2014; 66: 407-417https://doi.org/10.1002/art.38219
- Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma.Eur J Intern Med. 2010; 21: 114-117https://doi.org/10.1016/j.ejim.2010.01.004
- Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA.Rheumatol Oxf Engl. 2008; 47: 976-979https://doi.org/10.1093/rheumatology/ken201
- Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort.Scand J Rheumatol. 2011; 40: 404-406https://doi.org/10.3109/03009742.2011.569753
- Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study.J Rheumatol. 2010; 37: 125-130https://doi.org/10.3899/jrheum.090677
- Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening.J Rheumatol. 2017; https://doi.org/10.3899/jrheum.160817
- Validation of a new immunoenzymatic method to detect antibodies to RNA polymerase III in systemic sclerosis.Clin Exp Rheumatol. 2007; 25: 373-377
- Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies.Arthritis Rheum. 2006; 54: 3051-3056https://doi.org/10.1002/art.22043
Article info
Publication history
Published online: August 03, 2017
Accepted:
July 26,
2017
Received in revised form:
July 23,
2017
Received:
July 19,
2017
Footnotes
☆The authors declare no conflict of interest.
Identification
Copyright
© 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
